BioSpace News Archive

Evotec SE announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials.

The global healthcare satellite connectivity market has grown over the years and is expected to progress in the near term as well.

As ventures keep on advancing toward working in a totally computerized, the medical device producers and clients are finding that the move to digital conveys a ton a number of problems.

The RNA analysis/transcriptomics market may gain immense growth across the assessment period of 2019-2029 on the back of the escalating advancements across the transcriptomics sector.

The rising number of road accidents, coupled with the increasing popularity of medical tourism worldwide is a prime factor boosting the growth of the global ambulance services market during the forecast period, set between 2020 and 2030.

Hansa Biopharma AB, Reg. No. 556734-5359, with registered office in Lund, gives notice to Annual General Meeting on Wednesday May 12, 2021.

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced the abstract results of the final 5 year immune response data of the Phase IIb clinical trial at the 2021 AACR Annual Meeting.

Lannett Company, Inc. announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act.

Kraig’s joint venture with Kings is tied to the previously announced exclusive spider silk purchase and sales agreement valued at up to US$40 million